• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses

tetano

Editor, Senior Moderator
Adv Healthc Mater. 2017 Sep 25. doi: 10.1002/adhm.201700748. [Epub ahead of print]
[h=1]Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses.[/h] Schandock F[SUP]1[/SUP], Riber CF[SUP]2[/SUP], R?cker A[SUP]1[/SUP], M?ller JA[SUP]1[/SUP], Harms M[SUP]1[/SUP], Gajda P[SUP]3[/SUP], Zuwala K[SUP]3[/SUP], Andersen AHF[SUP]3[/SUP], L?vschall KB[SUP]2[/SUP], Tolstrup M[SUP]3[/SUP], Kreppel F[SUP]1[/SUP], M?nch J[SUP]1[/SUP], Zelikin AN[SUP]2,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Viral pathogens continue to constitute a heavy burden on healthcare and socioeconomic systems. Efforts to create antiviral drugs repeatedly lag behind the advent of pathogens and growing understanding is that broad-spectrum antiviral agents will make strongest impact in future antiviral efforts. This work performs selection of synthetic polymers as novel broadly active agents and demonstrates activity of these polymers against Zika, Ebola, Lassa, Lyssa, Rabies, Marburg, Ebola, influenza, herpes simplex, and human immunodeficiency viruses. Results presented herein offer structure-activity relationships for these pathogens in terms of their susceptibility to inhibition by polymers, and for polymers in terms of their anionic charge and hydrophobicity that make up broad-spectrum antiviral agents. The identified leads cannot be predicted based on prior data on polymer-based antivirals and represent promising candidates for further development as preventive microbicides.
? 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


[h=4]KEYWORDS:[/h] Zika virus; broad spectrum antivirals; microbicides; polyanions; polymers

PMID: 28945945 DOI: 10.1002/adhm.201700748
 
Back
Top Bottom